Your browser doesn't support javascript.
loading
Quantitative radiomic profiling of glioblastoma represents transcriptomic expression.
Kong, Doo-Sik; Kim, Junhyung; Ryu, Gyuha; You, Hye-Jin; Sung, Joon Kyung; Han, Yong Hee; Shin, Hye-Mi; Lee, In-Hee; Kim, Sung-Tae; Park, Chul-Kee; Choi, Seung Hong; Choi, Jeong Won; Seol, Ho Jun; Lee, Jung-Il; Nam, Do-Hyun.
Afiliación
  • Kong DS; Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea.
  • Kim J; Institute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.
  • Ryu G; Department of Health Science and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Republic of Korea.
  • You HJ; Institute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.
  • Sung JK; Department of Health Science and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Republic of Korea.
  • Han YH; Institute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.
  • Shin HM; Department of Health Science and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Republic of Korea.
  • Lee IH; Department of Computer Science, Korea University, Seoul, Republic of Korea.
  • Kim ST; Medical System Research Department, Convergence Technology Institute, Hyundai Heavy Industries, Co., Ltd, Ulsan, Republic of Korea.
  • Park CK; Institute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.
  • Choi SH; Department of Health Science and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Republic of Korea.
  • Choi JW; Institute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.
  • Seol HJ; Department of Radiology, Samsung Medical Center, Seoul, Republic of Korea.
  • Lee JI; Department of Neurosurgery, Seoul National University Hospital, Seoul, Republic of Korea.
  • Nam DH; Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea.
Oncotarget ; 9(5): 6336-6345, 2018 Jan 19.
Article en En | MEDLINE | ID: mdl-29464076
Quantitative imaging biomarkers have increasingly emerged in the field of research utilizing available imaging modalities. We aimed to identify good surrogate radiomic features that can represent genetic changes of tumors, thereby establishing noninvasive means for predicting treatment outcome. From May 2012 to June 2014, we retrospectively identified 65 patients with treatment-naïve glioblastoma with available clinical information from the Samsung Medical Center data registry. Preoperative MR imaging data were obtained for all 65 patients with primary glioblastoma. A total of 82 imaging features including first-order statistics, volume, and size features, were semi-automatically extracted from structural and physiologic images such as apparent diffusion coefficient and perfusion images. Using commercially available software, NordicICE, we performed quantitative imaging analysis and collected the dataset composed of radiophenotypic parameters. Unsupervised clustering methods revealed that the radiophenotypic dataset was composed of three clusters. Each cluster represented a distinct molecular classification of glioblastoma; classical type, proneural and neural types, and mesenchymal type. These clusters also reflected differential clinical outcomes. We found that extracted imaging signatures does not represent copy number variation and somatic mutation. Quantitative radiomic features provide a potential evidence to predict molecular phenotype and treatment outcome. Radiomic profiles represents transcriptomic phenotypes more well.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Oncotarget Año: 2018 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Oncotarget Año: 2018 Tipo del documento: Article